INTRODUCTION
Histone deacetylases (HDACs) play a crucial role in regulating gene expression and are considered a potential epigenetic target for cancer therapy. [1] [2] [3] Acetylation of histone proteins in promoter regions of genes has been found to activate gene transcription and is highly regulated by HDACs and histone acetyltransferases. 4, 5 Overexpression of HDACs induces histone hypoacetylation, resulting in chromatin condensation and thereby leading to transcriptional repression and epigenetic silencing. 1, 6 This aberrant epigenetic suppression of gene expression may result in uncontrolled cell proliferation and arrested differentiation leading to malignancy. 7 HDAC inhibitors (HDACIs) can reactivate gene expression and promote cell-cycle arrest, differentiation, and apoptosis through the induction of histone acetylation resulting in chromatin relaxation increasing the accessibility of transcription factors to their target genes. 1, 5, 8, 9 Pracinostat, 3-(2-butyl-1-(2-diethylaminoethyl)-1H-benzoimidazol-5-yl)-N-hydroxyacrylami-hydrochloride, is a potent pan-HDACI that has approximately twice the potency of vorinostat. 10 In vivo studies have demonstrated favorable pharmacokinetic (PK) properties of pracinostat, with a 4.1-fold increased oral bioavailability and a 3.3-fold increased half-life (t 1/2 ) when compared with vorinostat. 10 Furthermore, in contrast to vorinostat, pracinostat has been found to accumulate in tumor tissue and induce a dose-dependent sustained elevation in the histone H3 acetylation (AcH3) levels in mice models of acute myeloid leukemia (AML) and human colorectal cancer. 10, 11 These PK and pharmacodynamic (PD) properties of pracinostat have been confirmed in 2 studies conducted in patients with advanced solid tumors. 12, 13 Despite elevation in the target efficacy biomarker, AcH3 in peripheral blood mononuclear cells (PBMCs), the antitumor efficacy of pracinostat was not observed, with stable disease documented as the best response to treatment in 21% 13 and 32% 12 of the patients, respectively. Given the higher sensitivity of leukemia and lymphoma to pracinostat, 10 as demonstrated in preclinical studies, we conducted a multicenter phase 1 dose escalation study to assess the safety, tolerability, PKs, PDs, and efficacy of pracinostat in patients with advanced hematological malignancies.
MATERIALS AND METHODS
The current multicenter study was developed jointly by the initial pracinostat developer, S*Bio Pte Ltd, and the investigators. The clinical trial registration number is NCT00741234. The study was conducted according to the standards of good clinic practice and as per institutional research policies and procedures. The study protocol was approved by the Institutional Review Board and ethics committee at each center.
Patient Population
Patients aged 18 years with an advanced hematological malignancy (recurrent or refractory AML, high-risk myelodysplastic syndrome [MDS; defined by an International Prognostic Scoring System risk category of intermediate-1], multiple myeloma, myelofibrosis, indolent or aggressive non-Hodgkin lymphoma, or Hodgkin lymphoma) who failed therapy, developed disease recurrence, or were ineligible for conventional therapy or allogeneic stem cell transplantation (SCT) were eligible. Patients had to have an Eastern Cooperative Oncology Group performance status of 2; adequate renal, hepatic, and cardiac function (total bilirubin 1.5 times the upper limit of normal, aspartate aminotransferase and alanine aminotransferase 2.5 times the upper limit of normal, serum creatinine <1.6 mg/dL, and a left ventricular ejection fraction 50%); and no clinically significant comorbidities.
14 Major exclusion criteria were central nervous system involvement, concomitant treatment with other HDACIs, malabsorption, use of hydroxyurea or any investigational agent within 14 days or 5 half-lives of study enrollment, major surgery within the past 4 weeks, therapy for malignancy within the past 3 weeks, uncontrolled cardiovascular or cerebrovascular events within the past 6 months, and a Fridericia correction formula QT interval (measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle [QTcF] ) >450 milliseconds in males and >470 milliseconds in females. All patients provided written informed consent before study enrollment.
Study Design and Treatment
The current study was a phase 1, multicenter, open-label, single-agent, dose escalation study designed to assess the safety, tolerability, efficacy, and PK and PD properties of pracinostat in patients with advanced hematologic malignancies. Patients were assigned to 7 dose cohorts (10 mg to 120 mg) using a 3 1 3 dose escalation design to determine the maximum tolerated dose (MTD). Pracinostat was administered orally once daily, every other day, 3 days a week, for 3 consecutive weeks in a 28-day cycle. The MTD was defined as the lowest dose level at which 2 patients out of 6 who completed at least 1 cycle of treatment experienced a dose-limiting toxicity (DLT). The recommended phase 2 dose (RP2D) was defined as the dose level immediately below the MTD. Once the RP2D was defined, up to 10 patients with intermediate or highrisk MDS and up to 10 patients with AML were added for a total of up to 26 patients treated at the RP2D to assess the antitumor activity and confirm the tolerability and PK properties of pracinostat.
Given the known synergy between hypomethylating agents and HDACIs, the study protocol was amended to include a second cohort of patients (arm 2) to assess the safety, tolerability, and efficacy of pracinostat plus azacitidine (AZA) in patients with intermediate or high-risk MDS who were not previously treated with AZA. 15 AZA was given at a dose of 75 mg/m 2 daily for 7 days in a 28-day cycle in combination with pracinostat, which was given at a dose of 60 mg starting on day 1.
Efficacy and Safety
For patients in arm 1 (pracinostat), response assessment was performed using the International Working Group criteria. [16] [17] [18] [19] [20] [21] For patients in arm 2 (AZA plus pracinostat), response was considered when complete remission (CR) or CR with incomplete platelet recovery was achieved. CR was defined as bone marrow blasts <5% with complete recovery of peripheral counts (neutrophil count >1000/ uL and platelet count >100,000/uL). CR with incomplete platelet recovery was defined using the same criteria except for a platelet count <100,000 uL and transfusion independence. Progression-free survival (PFS; time from the start of therapy to disease progression, death, or last follow-up) and overall survival (OS; time from the start of therapy to the date of death or last follow-up) were assessed.
Original Article
Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). DLTs were defined as AEs occurring during the first cycle of treatment and fulfilling 1 of the following criteria: grade 3 nonhematologic treatment-related AE (TRAE) including grade 3 nausea and vomiting that was uncontrolled with optimal therapy; a dose delay of >2 weeks or missing 4 doses within a cycle due to TRAEs or laboratory abnormalities; grade 4 neutropenia lasting 7 days or grade 3 neutropenia associated with fever and/or infection (malignant lymphoma only); and grade 4 thrombocytopenia or grade 3 thrombocytopenia plus bleeding (malignant lymphoma only). In the event of a DLT, pracinostat was withheld until resolution of the toxicity, after which it could be resumed at a reduced dose.
PK and PD Analysis
Blood samples for PK analysis were drawn before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, and 30 hours after dosing on days 1 and 15 of cycle 1. Pre-dose PK assessment also was performed on day 8 of cycle 1 of treatment, excluding additional patients enrolled at the RP2D. Plasma concentrations of pracinostat were determined using a validated liquid chromatography-tandem mass spectrometry method. Noncompartmental methods were used to estimate the area under the concentration versus time curve from time zero to infinity (AUC 0-inf ). The t 1/2 was estimated using the extrapolation of the terminal segment of the log-linear concentration-time curve to infinity including at least the last 3 points. Peak plasma concentration (C max ) and the mean time to peak concentration (T max ) were estimated from the plasma drug concentration-time curve. PK parameters were calculated using validated WinNonlin software (version 5.2; Pharsight, Mountain View, California).
For PD evaluation, blood samples were collected for isolation of PBMCs, a surrogate for tumor tissue, to test for changes in the AcH3 levels. Samples were obtained before dosing and at 3 and 24 hours after dosing on days 1 and 15 of cycle 1. Levels of AcH3 in PBMCs were determined using a validated Western blot or enzyme-linked immunoadsorbent assay. 12 Details regarding blood sample collection, processing, PBMC extraction, and measurement of the pracinostat concentration in plasma and AcH3 levels in PBMCs have been reported previously. 12 
Statistical Analysis
The efficacy analysis included all subjects who completed 2 cycles of therapy and had at least 1 follow-up tumor assessment. The safety population included all subjects who received at least 1 dose of pracinostat, whereas the DLT analysis was performed among those patients who received at least 75% of cycle 1. Two-sided, exact 95% confidence intervals were used to estimate the response rates. The median PFS and OS were estimated using the Kaplan-Meier method.
RESULTS

Patient Characteristics and Evaluable Populations Arm 1 (pracinostat)
From April 2007 to February 2012, a total of 44 patients with advanced hematological malignancies were enrolled. Baseline demographics and disease characteristics are summarized in Table 1 . The median age of the patients was 70 years (range, 37-84 years), with a male From May 2011 to February 2012, a total of 10 patients with MDS were enrolled. The median age of the patients was 65 years (range, 18-73 years), with a female predominance (70%). Baseline characteristics are shown in Table  1 . Eight patients had therapy-related MDS. On cytogenetic analysis, 6 patients had complex karyotype, 3 had monosomy 7, and 1 had translocation (6;9). Four patients received prior therapy for MDS (decitabine in 2 patients and lenalidomide in 2 patients). Patients received a median of 4 cycles of therapy (range, 2-9 cycles).
Safety and Toxicity Arm 1 (pracinostat)
Of the 44 patients in arm 1, 34 (77%) experienced at least 1 TRAE ( Table 2 ). The most common nonhematological TRAEs were fatigue (41%), nausea (30%), anorexia (23%), diarrhea (16%), and vomiting (14%). These events were mild to moderate in severity and were more frequent at higher dose levels. Nine patients (20%) experienced a TRAE of grade 3, with the most common nonhematological AEs being fatigue (11%), infections (9%), and QTc prolongation (5%). Thrombocytopenia (14%) was the most common hematological AE and was Abbreviations: ALT, alanine aminotransferase; AZA, azacitidine; QTc, corrected QT interval (measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle). a Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). experienced at grade 3 with pracinostat doses 80 mg. AEs leading to a dose reduction or dose interruption of pracinostat occurred in 27% and 34%, respectively, of the patients. Discontinuation of pracinostat due to an AE was required in 11 patients (25%), 3 of whom discontinued therapy due to a TRAE including QTc interval prolongation, fatigue, and elevated troponins. DLTs were reported in 5 patients (13%) and included grade 3 QTc interval prolongation (2 patients treated at doses of 40 mg and 100 mg, respectively), fatigue (2 patients treated at doses of 100 mg), and febrile neutropenia (1 patient treated at a dose of 120 mg). Although the MTD was not reached, multiple dose reductions were required for patients treated at the dose of 120 mg, which prompted its selection as the MTD and expansion of the 100-mg dose cohort. Because the majority of patients did not tolerate repeated cycles at doses >60 mg, this dose level was determined to be the RP2D.
Arm 2 (AZA plus pracinostat)
All 10 patients reported a TRAE ( Table 2 ). The most common nonhematological TRAEs were nausea (100%), vomiting (80%), fatigue (60%), and constipation (50%). Eight patients experienced a TRAE of grade 3. Thrombocytopenia (60%) and neutropenia (40%) were the most frequently reported hematological TRAEs. Three patients required a dose reduction of pracinostat due to an AE.
Pharmacokinetics
A total of 23 patients were assessed for day 1 PKs and 18 patients were assessed for day 15 PKs (Table 3) . Due to the small number of patients, the 10-mg and 20-mg dose cohorts were excluded from the analysis. Pracinostat demonstrated rapid absorption, with a T max reached in 0.8 to 1.3 hours, followed by biexponential disposition (Fig. 1) . The mean t 1/2 ranged from 7.0 to 14.1 hours. The mean AUC 0-inf and C max demonstrated a dose proportional 
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Cancer December 15, 2017 increase between 40 mg and 120 mg on day 1. With the exception of the 100-mg dose level, no significant accumulation was observed between day 1 and day 15 after repeated dosing of the drug. There was moderate accumulation at the 100-mg dose level; the mean AUC 0-inf and C max on day 15 were 1985 ng*h/mL and 314 ng/mL, respectively, compared with 1171 ng*h/mL and 187 ng/ mL, respectively, on day 1. Plasma concentrations above the 50% inhibitory concentration of pracinostat for HDAC 1, 2, and 3 were reached at all dose levels. PK parameters for pracinostat were not affected by the administration of AZA.
Pharmacodynamics
Information regarding PBMCs for PD analysis was obtained from 10 subjects. Although AcH3 levels were found to be increased across all dose levels, a dosedependent increase was not observed. The maximal increase in AcH3 levels was observed at the 3-hour postdose sampling point, with levels found to be slightly sustained at 24 hours on day 15 (Fig. 2) .
Response Rates Arm 1 (pracinostat)
A total of 32 patients were evaluable for response, with the remaining 12 patients excluded due to inadequate drug exposure. There were 2 responders (6%), 1 patient achieved a CR, and 1 patient achieved complete cytogenetic response. Both patients had AML, were enrolled at the 80-mg and 120-mg dose levels, completed 11 cycles and 8 cycles of pracinostat, and had a PFS of 362 days and 197 days, respectively. Among the remaining 30 patients, 20 had stable disease (67%) and 10 experienced progressive disease (33%). The median duration of follow-up was 2.7 months (range, 2.1-11.8 months). The median OS was 362 days (95% confidence interval, 114.0 days to not available). Thirteen patients (30%) died; the causes of death included disease progression (4 patients), infection (6 patients), respiratory failure (2 patients), and hemorrhagic stroke (1 patient).
Arm 2 (AZA plus pracinostat)
Six patients achieved a CR and 3 achieved a CR without platelet recovery, for an overall response rate (ORR) of 90%. The median number of cycles to response was 3 (range, 1-6 cycles). Five patients achieved a cytogenetic response (4 complete cytogenetic responses and 1 major cytogenetic response). Five patients were bridged successfully to SCT. A total of 3 patients developed disease recurrence at 4 months, 7 months, and 10 months, respectively, including 1 recurrence that occurred after SCT. The 2-year disease-free survival and OS rates were 57% and 56%, respectively; the median OS was not yet reached at the time of last follow-up (Fig. 3) . Four patients (40%) died: 3 died after developing disease recurrence and 1 patient died in CR after undergoing SCT.
DISCUSSION
To the best of our knowledge, the current study is the first clinical trial using pracinostat in patients with advanced hematological malignancies. Pracinostat was found to be well tolerated, demonstrated excellent PK properties, and induced histone acetylation in a non-dose-dependent fashion. Although the MTD of pracinostat was declared to be 120 mg, the RP2D was determined to be 60 mg due to the multiple dose reductions required with higher doses. Comparable to previous reports, these findings suggest that toxicity assessment during the first cycle of therapy may be insufficient to assess for DLTs of a drug. 22 Pracinostat demonstrated limited but significant antitumor activity in patients with advanced hematological malignancies. Although the majority of patients experienced prolonged disease stabilization, 2 patients with AML who were treated at or below the MTD achieved a response.
Consistent with previous studies of pracinostat, the most common toxicities reported in the current study were gastrointestinal symptoms, fatigue, and thrombocytopenia. 12, 13 Toxicities were mostly mild to moderate in severity and were controlled easily with either standard medical management or dose reduction. High-grade thrombocytopenia was observed at doses 80 mg, as in previous reports. 12, 13 DLTs occurred at doses 40 mg, and included QTc interval prolongation, fatigue, and febrile neutropenia. In contrast to the findings of the current study and that of Yong et al, 13 Razak et al 12 used an alternative dosing schedule of continuous 5-day dosing every 2 weeks and demonstrated the early emergence of grade 3 TRAEs and DLTs at lower doses of pracinostat (20 mg) compared with 40 mg in the current study and that of Yong et al, 13 thereby suggesting better tolerance of the every-other-day schedule. Furthermore, the everyother-day schedule has been associated with superior therapeutic efficacy as demonstrated in preclinical studies and confirmed by Yong et al, who reported a dose-dependent escalation in AcH3 levels among patients with refractory solid tumors. 10, 13 This improved efficacy may be attributed to the continuous exposure to pracinostat provided by this regimen. For these reasons, this schedule has been selected for subsequent phase 2 studies.
PK analysis of pracinostat demonstrated favorable properties with rapid absorption followed by biexponential disposition, which is comparable to the solid tumor experience. 12, 13 There was a dose-dependent increase in the plasma concentration of pracinostat, with a prolonged t 1/2 reaching 14 hours, which was significantly longer when compared with the t 1/2 of 1 to 2 hours for vorinostat and belinostat. 23, 24 This improved t 1/2 allows for the intermittent dosing of pracinostat without jeopardizing its efficacy. Unlike previous studies of pracinostat, drug accumulation was observed at the 100-mg dose level, which correlated with the intolerance observed with repeated drug administration. As a result, 60 mg was declared as the RP2D, which is in keeping with the results published by Razak et al and Yong et al. 12, 13 Despite the sustained elevation of AcH3 levels across all doses, we did not find a dose-dependent increase as reported by Yong et al. 13 In vitro, the AcH3 levels were found to vary significantly among the different subtypes of pracinostat-treated PBMCs, with CD20-positive B lymphocytes demonstrating the highest levels and CD16-positive monocytes demonstrating the lowest levels of AcH3. 11 Therefore, AcH3 levels in pracinostat-treated PBMCs are not comparable in patients with hematological malignancies due to the abnormal variation in the percentages of the different hematopoietic cells.
There is a dynamic, intricate interaction between DNA methylation and histone deacetylation that induces gene repression. DNA methyltransferases (DNMTs) catalyze the methylation of CpG islands in the promotor region of tumor suppressor genes, which subsequently bind to methyl-CpG-binding proteins recruiting transcriptional corepressors, including HDACs, inducing histone deacetylation and chromatin condensation and thereby repressing gene transcription. 5, 25, 26 In vitro, HDACs alone could not transcriptionally reactivate densely methylated genes without the prior use of a DNMT inhibitor, signifying the dominance of DNA methylation in epigenetic silencing and the synergistic activity between HDAC and DNMT inhibitors. 15, 27 This synergy has been translated clinically, with numerous trials demonstrating the promising activity of the combination in both patients with AML and those with MDS. 25, [28] [29] [30] [31] Response rates increased from 10% to 20%, as achieved after a median of 3 to 4 cycles when using either agent alone, to 30% to 46%, as achieved after a median of 2 cycles with the combination. This compares favorably with the results of the current study; we observed an ORR of 90% in patients with higher-risk MDS who were treated with AZA plus pracinostat. Based on these results, two phase 2 studies have been conducted to determine the efficacy of this combination in both patients with higher-risk MDS and AML. 32, 33 Despite the lack of efficacy noted in patients with higher-risk MDS due to a high rate of early discontinuation because of toxicity, there was significant activity in patients with AML, with an ORR of 52% lasting for a median of 13.2 months. The median OS among patients with AML was 19.1 months, which compares favorably with the historic AZA data. 34 The results of the current study confirm the safety and efficacy of pracinostat in patients with advanced hematological malignancies, with significant activity noted among patients with AML and MDS, especially in combination with AZA. Given its potency and synergy with DNMT inhibitors, randomized phase 3 trials of pracinostat plus AZA for both patients with MDS and those with AML currently are ongoing.
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